Literature DB >> 18759201

Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer.

J Trojan1, N Lubomierski, T Lehnert, K Engels, S Zeuzem, W O Bechstein.   

Abstract

Some patients with initially unresectable hepatic colorectal cancer metastases can be effectively treated with neoadjuvant chemotherapy to allow operative resection in curative intent. Here, we report on a patient with unresectable locoregional recurrence of colon cancer, which was down-staged using combination chemotherapy with infusional 5-fluorouracil, folinic acid, oxaliplatin and cetuximab. After 12 weeks of therapy a partial response was documented and 3 weeks later the tumor was completely resected without increased perioperative morbidity. Therefore, neoadjuvant treatment with molecular targeted agents in combination with chemotherapy can also be an option to enable selected patients with locoregional recurrence to undergo surgical resection in curative intent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759201     DOI: 10.1055/s-2007-963717

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  2 in total

1.  Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.

Authors:  Qing Zhang; Hong Chen; Qin Li; Yunjin Zang; Xinguo Chen; Weilong Zou; Letian Wang; Zhong-Yang Shen
Journal:  Invest New Drugs       Date:  2011-08-02       Impact factor: 3.850

2.  The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor.

Authors:  Elias Nerad; Andrea Delli Pizzi; Doenja M J Lambregts; Monique Maas; Sharan Wadhwani; Frans C H Bakers; Harrie C M van den Bosch; Regina G H Beets-Tan; Max J Lahaye
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.